Founded in 1999, PELVIPHARM is a spin-off from the University of Versailles-Saint-Quentin-en-Yvelines (France) relying on multi-disciplinary talents (medical doctor, pharmaco-economist, veterinarian, pharmacists and PhDs) who deliver both high quality academic standards and reliable contract research services :
- Preclinical studies based on validated efficacy models including delivery of protocol development, study conduct, report, communication and peer-reviewed publication
- Guidance for selection of new chemical entities including testing with targeted assays according to potential mechanisms of action
- Identification of new properties or attributes supporting differentiation of medications within the class or between classes
- Advice in clinical development for new therapeutic indications or enhancements to address unmet medical need or significant commercial opportunities
PELVIPHARM has leading scientific and medical capabilities from unique expertise and experience in pathophysiology, pharmacology, clinical research and medical practice across a range of therapeutic areas including urology (BPH, OAB, NDO, SCI, SUI, IC …), sexual medicine (ED, PE, FSD …) and cardiovascular (Hypertension, Atherosclerosis, Myocardial Infarction …), metabolism and eating disorders (Metabolic Syndrome, Obesity, Diabetes ...)
PELVIPHARM provides customized services to clients according to their outsourcing needs, using experimental models based on the most recent exploration methods.
PELVIPHARM can give you the unique expertise and the experience of a team gathered over the years.
News and next meetings
Pelvipharm, your partner for preclinical research. We wish you the very best for the new year and a......
Recently accepted paper in BMC Urol
Silodosin improves functional consequences of lower urinary tract obstruction secondary to benign pr......
Recently accepted paper in Sexual Medecine
Extracorporeal Shock Waves Therapy Delivered by Aries Improves Erectile Dysfunction in Spontaneously......
To schedule a meeting, please contact usLatest website updates
New abstract/poster available for download
Low intensity-shockwave therapy (Li-ESWT) delivered by Aries® improves erectile function and decreases cavernosal fibrosis of spontaneously hypertensive rats (SHR) presented at EAU 2018 in Copenhagen, Danemark, 16-20 March, Giuliano et al.
New experimental skills developed
Vaginal blood flow engorgement measurement by Laser Doppler Flowmetry (rat/guinea pig/rabbit)
New model developped
